Lg Cwd

New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.

April 7, 2020

Lilly is allowing anyone with commercial insurance, and without insurance at all, to fill their monthly prescription of Lilly insulin for $35, according to a press release issued on April 7, 2020. This new program, called the Lilly Insulin Value Program, is in response to the crisis caused by COVID-19.

“Too many people in the U.S. have lost their jobs because of the COVID-19 crisis, and we want to make sure no one goes without their Lilly insulin,” said Mike Mason, president, Lilly Diabetes. “We’ve been providing affordability solutions for a long time, but more is needed to help people during this unprecedented period. People with commercial insurance, as well as those without insurance at all, are eligible, and the process is quick and simple. We want people who need help to call us.”

According to the press release, “The savings can be obtained by calling the Lilly Diabetes Solution Center at (833) 808-1234. The Solution Center is open 8 am to 8 pm (EDT) Monday through Friday. Representatives at the Solution Center will help people with diabetes obtain a card in the most convenient way for them, including through email or the U.S. mail. A card can typically be received within 24 hours by email. If you already have a co-pay card from the Lilly Diabetes Solution Center for an amount higher than $35, no action is necessary. Active co-pay cards have been re-set to a $35 co-pay.”

“Representatives at the Solution Center can also direct people to affordability options that may reduce their out-of-pocket costs further – such as free insulin for people with minimal income, or no income at all, that has been donated by Lilly to non-profit organizations.”

Lilly also included information about their supply chain security, stating that they do not currently anticipate shortages of any form of insulin from the COVID-19 crisis.

For more information, you can read through the full press release from Lilly, and CWD is staying up-to-date on information regarding insulin access resources.